IPO

Suraksha Diagnostic Limited IPO

Mainboard

Healthcare Service Provider

Listed On: Dec 6, 2024 at ₹ 438.0(NSE)

₹ 14994 /34 Shares

Check Allotment

29 Nov, 2024

Open Date

03 Dec, 2024

Close Date

04 Dec, 2024

Allotment Date

06 Dec, 2024

Listing Date
Price Summary

Last Closing

301.00 (-31.75%)

52 Week High

449.00

52 Week Low

231.00

Last Update

17-Oct-2025 3:30 PM
Suraksha Diagnostic IPO Issue Details
  • Issue Price ₹420-441 per equity share
  • Face Value ₹2 Per Equity Share
  • Total Issue Size 1,91,89,330 shares(aggregating up to ₹846.25 crore)
  • Offer For Sale 1,91,89,330 shares(aggregating up to ₹846.25 crore)
  • Listing at BSE, NSE
  • List Price 438.0(NSE)
  • Listing Date 2024-12-06
  • Lead Manager ICICI Securities Limited
    Nuvama Wealth Management Limited
    SBI Capital Markets Limited
  • Registrar Kfin Technologies Limited
Market Lot Size

Investors can bid for a minimum of 34 shares and in multiples thereof. The following table depicts the minimum and maximum investment by Retail Investors and HNI in terms of shares and amount.

ApplicationLotsSharesAmount
Retail (min)134₹14,994
Retail(max)13442₹1,94,922
Suraksha Diagnostic IPO Reservation

Suraksha Diagnostic IPO offers total 1,91,89,330 shares. Out of which 38,37,867 (20%) allocated to QIB, 28,78,400 (15%) allocated to NII,67,16,266 (35%) allocated to RII, NA (NA%) allocated to employees and 57,56,797 (30%) allocated to Anchor investors.

Investor CategoryShares OfferedMaximum Allottees
Anchor Investor Shares Offered57,56,797 (30%)
QIB Shares Offered38,37,867 (20%)
NII (HNI) Shares Offered28,78,400 (15%)
bNII < ₹10L19,18,934 (10%)
sNII < ₹10L9,59,466 (5%)
Retail Shares Offered67,16,266 (35%)
Total Shares Offered1,91,89,330 (100%)
Suraksha Diagnostic IPO Documents
DRHP
RHP
ANCHOR
Suraksha Diagnostic IPO Details


Suraksha Diagnostic IPO is a book-built issue of ₹846.25 crores, The total issue size is ₹846.25 crores. The IPO of Suraksha Diagnostic is priced at ₹420-441 per equity share, which has a face value of ₹2 Per Equity Share each, IPO bidding starts from Nov 29, 2024 and ends on Dec 3, 2024. The allotment for Suraksha Diagnostic IPO will be finalized on Dec 4, 2024. Suraksha Diagnostic IPO will be listed on BSE, NSE, with a tentative listing date fixed as Dec 6, 2024. The company shall list its equity shares on the BSE, NSE. Kfin Technologies Limited is the registrar of the issue.

Retail investors can bid for a minimum of 34 shares, extendable to 14,994. The book-running lead manager for the IPO is/are ICICI Securities Limited, Nuvama Wealth Management Limited, SBI Capital Markets Limited.

The total issue ₹846.25 crore and having Offer for Sale (OFS) of 1,91,89,330 shares to mop up ₹846.25 crore.

The Suraksha Diagnostic IPO sets its price band at 420-441 for each share. A single application for Suraksha Diagnostic Limited IPO must contain at least 34 shares. Sentiment investors need to invest a minimum of 34 through their retail account. For investors to prevent oversubscription issues, they should submit bids at the cutoff price, which estimates about ₹14,994

Read More
Suraksha Diagnostic IPO Subscription Analysis And Details
Retail
0.94x
QIB
1.74x
NII
1.40x
bNII
1.53x
sNII
1.16x
Total
1.27x
As onQIBNII
bNII   sNII		RetailTotal
Shares Offered / Reserved3,837,8672,878,400
1,918,934    959,466		6,716,26613,432,533
Day 1 29-11-24 05:00 PM
0.00 x0.04
0.02 x   0.08 x		0.20 x0.11 x
Day 2 02-12-24 05:00 PM
0.00 x0.13
0.08 x   0.23 x		0.45 x0.25 x
Day 3 03-12-24 05:00 PM
1.74 x1.40
1.53 x   1.16 x		0.94 x1.27 x
Total No of Applications
1,47,938
Subscription on the basis of Applications
Retail:0.74x BHNI:0.21x SHNI:1.05x
Suraksha Diagnostic Valuations
EPS Pre IPO ₹4.44/-
EPS Post IPO ₹5.89/-
P/E Pre IPO 99.31
P/E Post IPO 74.89
ROE 14.09%
ROCE 21.46%
Debt/Equity 0.20
RoNW 14.09%
PAT Margin 10.57
Price to Book Value 13.10
Suraksha Diagnostic Company Financials
In Crs.
In Cr.
31-Mar-2431-Mar-2331-Mar-22
Assets300.21281.20275.96
Revenue222.26193.69225.77
Profit After Tax23.136.0720.82
Net Worth179.41155.93145.84
Reserves & Surplus170.88147.40137.31
Total Borrowing8.6414.0119.03
About Suraksha Diagnostic Company

On March 15, 2005, Suraksha Diagnostic Limited began its operation as a leading technology-driven diagnostic chain in India. The company provides integrated pathology, radiology, and medical consultancy services under one umbrella with an excellent operational network. As of date, more than 2,300 specialized tests in various disciplines of medicine meet diverse health needs.

Comprehensive Diagnostic Network:Suraksha Diagnostic runs a state-of-the-art central reference laboratory supported by 8 satellite laboratories and 194 customer contact points, including 48 diagnostic centers and 146 sample collection centers. This extensive infrastructure thus provides seamless patient experience, convenient and accessible across eastern and northeastern India.

Besides offering diagnostic services, over 120 polyclinics function in 43 diagnostic centers with more than 750 doctors across the organization to offer in-house medical consultations for improving patient care.

Read More
Suraksha Diagnostic - Promoter(s)

Dr. Somnath Chatterjee

Ritu Mittal

Satish Kumar Verma

Pre Issue Share Holding : 61.07%

Post Issue Share Holding : 48.78%

Suraksha Diagnostic IPO - Issue Objectives
1

The Company will not receive any proceeds from the Offer for sale and all proceeds will go to the Selling Shareholders.

Suraksha Diagnostic IPO - Anchor Investors

Suraksha Diagnostic raises Rs 254 cr via anchor subscribed ahead of Rs 846 Crore IPO.

Nippon Life India, Kotak Mutal Fund, Aditya Birla Sun Life Trustee, and Quant Mutual Fund are the biggest investors in the company through anchor book, acquiring 7.93 lakh equity shares worth Rs 35 crore each, while Carnelian Bharat Amritkaal Fund picked 6.8 lakh shares worth Rs 30 crore.

Mirae Asset, JM Financial, Bandhan Mutual Fund, Troo Capital, Intergrated Core Strategies, Tusk Investments Equity Fund, and Societe Generale are other investors participated in the anchor book.

Suraksha Diagnostic IPO - Peers Comparison
Company NameEPS (Basic)EPS (Diluted)NAV (per share) (Rs)P/E (x)RoNW (%)P/BV RatioFinancial statements
Suraksha Diagnostic Limited4.434.4333.66N/A14.09N/AConsolidated
Dr Lalchandani Labs Ltd43.0542.98221.4777.0820.350.07Consolidated
Metropolis Healthcare Ltd24.9524.87213.9889.6112.268.05Consolidated
Thyrocare Technologies Ltd13.4213.499.4865.5213.345.93Consolidated
Vijaya Diagnostic Centre Limited11.6211.5964.2186.419.779.91Consolidated

Notes:

  1. The P/E Ratio has been computed based on the closing market price of equity shares on July 12, 2024, divided by the Diluted EPS.
  2. Return on Net Worth (%) = Net profit after tax, as restated / Average shareholders' equity (including minority interest) as restated at year/period end.
  3. NAV is computed as the closing net worth (excluding minority interest) divided by the closing outstanding number of equity shares.
  4. Net worth means the aggregate value of the paid-up share capital of the Company and all reserves created out of profits and securities premium account and debit or credit balance of profit and loss account, after deducting the aggregate value of the accumulated losses, miscellaneous expenditure not written off, as per the restated balance sheet, but does not include reserves created out of revaluation of assets, write-back of depreciation as at year/period end, as per Restated Financial Statement of Assets and Liabilities of the Company.
Strength
Leading presence in eastern India’s diagnostic market with growth potential in a fragmented industry.
Provides comprehensive diagnostics, including pathology, radiology, and consultations.
Recognized brand with a focus on quality, supporting individual consumer business.
Equipped with advanced clinical infrastructure and skilled personnel for reliable services.
Weakness
The company’s business relies heavily on West Bengal, and any loss of business in this region may negatively impact overall performance.
The company depends on third-party vendors for testing equipment, and supply disruptions could affect operations.
The diagnostics industry is highly competitive, which could lead to price cuts that affect profits.
Contact Details

Suraksha Diagnostic

Plot No. DG-12/1, Action Area 1D, Premises No. 02-0327, New Town, Rajarhat Kolkata 700 156

+91 33 66059750

investors@surakshanet.com

https://www.surakshanet.com/

Registrar Contact Details

Kfin Technologies Limited

04067162222, 04079611000

sdl.ipo@kfintech.com

https://kosmic.kfintech.com/ipostatus/